Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines the results of PROUD-PV (NCT01949805) and CONTINUATION-PV (NCT02218047) studies investigating the use of ropeginterferon alfa-2b in low-risk polycythemia vera patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).